Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 10;10(5):1146.
doi: 10.3390/cells10051146.

Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis

Affiliations

Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis

Matteo Lucchini et al. Cells. .

Abstract

In recent years, an autoantibody directed against the 5'-citosolic nucleotidase1A (cN1A) was identified in the sera of sporadic inclusion body myositis (s-IBM) patients with widely variable sensitivity (33%-76%) and specificity (87%-100%). We assessed the sensitivity/specificity of anti-cN1A antibodies in an Italian cohort of s-IBM patients, searching for a potential correlation with clinical data. We collected clinical data and sera from 62 consecutive s-IBM patients and 62 other inflammatory myopathies patients. Testing for anti-cN1A antibodies was performed using a commercial ELISA. Anti-cN1A antibodies were detected in 23 s-IBM patients, resulting in a sensitivity of 37.1% with a specificity of 96.8%. Positive and negative predictive values were 92.0% and 60.6%, respectively. We did not find significant difference regarding demographic variables, nor quadriceps or finger flexor weakness. Nevertheless, we found that anti-cN1A-positive patients presented significantly lower scores in IBMFRS item 1 (swallowing, p = 0.045) and more frequently reported more severe swallowing problems, expressed as an IBMFRS item 1 score ≤ 2 (p < 0.001). We confirmed the low sensitivity and high specificity of anti-cN1A Ab in s-IBM patients with a high positive predictive value. The presence of anti-CN1A antibodies identified patients with a greater risk of more severe dysphagia.

Keywords: anti-cN1A antibodies; autoantibodies; inclusion body myositis; inflammatory myopathies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest regarding the content of this paper.

References

    1. Griggs R.C., Askanas V., DiMauro S., Engel A., Karpati G., Mendell J.R., Rowland L.P. Inclusion body myositis and myopathies. Ann. Neurol. 1995;38:705–713. doi: 10.1002/ana.410380504. - DOI - PubMed
    1. Askanas V., Alvarez R.B., Mirabella M., Engel W.K. Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis. Ann. Neurol. 1996;39:389–391. doi: 10.1002/ana.410390318. - DOI - PubMed
    1. Needham M., Corbett A., Day T., Christiansen F., Fabian V., Mastaglia F.L. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J. Clin. Neurosci. 2008;15:1350–1353. doi: 10.1016/j.jocn.2008.01.011. - DOI - PubMed
    1. Rose M. 188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul. Disord. 2013;23:1044–1055. doi: 10.1016/j.nmd.2013.08.007. - DOI - PubMed
    1. Tasca G., Monforte M., De Fino C., Kley R.A., Ricci E., Mirabella M. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve. 2015;52:956–962. doi: 10.1002/mus.24661. - DOI - PubMed

Publication types